Multiplikator Forward P/S: Surmodics (SRDX)

Surmodics, Inc. (SRDX) controls the synthesis of reagents, outsourcing only external catheter testing to contractors. After evaluating the forward P/S multiple on GURU.Markets, we find that 5.10 reflects the current metric volume, linking price to future sales. This complements the company's status as a key supplier of hydrophilic coatings for stents. Growth in shipments coupled with high margins creates operating leverage, reducing R&D costs.

Forward P/S is calculated as the ratio of the current market value of the business to projected annual revenue, reflecting the premium the market is willing to pay for future sales. The future P/S dynamics of the issuer allow for an assessment of how effectively the capitalization of Surmodics, Inc. (SRDX) prices in the stability of supplies from high-tech plants in the US and Ireland amid strict production sterility requirements.